On Feb. 7, 2013, the U.S. Food and Drug Administration (FDA) issued a proposal designed to help companies developing new treatments for patients in the early stages of Alzheimer’s disease. Read more.
FDA issues proposed guidelines for developing drugs for Alzheimer’s disease
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.